Cancer enzyme affects Parkinson's disease

See allHide authors and affiliations

Science  02 Nov 2018:
Vol. 362, Issue 6414, pp. 521-522
DOI: 10.1126/science.aav3986

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by rigidity, tremor, and slowness of movement, as well as a wide range of debilitating nonmotor symptoms (1). The neuropathology is characterized by loss of midbrain dopamine–producing neurons and the occurrence of intraneuronal protein aggregates, largely comprising the protein α-synuclein, that are distributed widely throughout the nervous system. Current treatments are focused on alleviating the impaired movement, and there is no therapy that slows PD progression. With almost 7 million patients worldwide, finding ways to prevent long-term neurodegeneration in PD and slow disease progression are vital goals. On page 557 of this issue, Kam et al. (2) describe a new molecular pathway that could explain why α-synuclein aggregates form in PD. Moreover, their findings suggest a pharmacological approach to slowing PD progression.